T-cell acute lymphoblastic leukemia
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| T-cell acute lymphoblastic leukemia | |
|---|---|
| File:T-ALL cells.jpg | |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Fatigue, pallor, bruising, bleeding, fever, infection |
| Complications | N/A |
| Onset | Childhood, adolescence |
| Duration | Variable |
| Types | N/A |
| Causes | Genetic mutations |
| Risks | Genetic predisposition, radiation exposure, chemical exposure |
| Diagnosis | Blood test, bone marrow biopsy, immunophenotyping, cytogenetic analysis |
| Differential diagnosis | B-cell acute lymphoblastic leukemia, acute myeloid leukemia, lymphoblastic lymphoma |
| Prevention | N/A |
| Treatment | Chemotherapy, radiation therapy, stem cell transplant |
| Medication | N/A |
| Prognosis | Variable, generally poorer than B-ALL |
| Frequency | Rare, accounts for 15% of acute lymphoblastic leukemia cases in children |
| Deaths | N/A |
T-cell acute lymphoblastic leukemia (T-ALL) is a subtype of acute lymphoblastic leukemia (ALL), a cancer of the white blood cells. T-ALL affects T cells, a type of lymphocyte that plays a key role in the immune response.
Epidemiology[edit]
T-ALL accounts for approximately 15% of ALL cases in children and 25% in adults. It is more common in males than in females, and its incidence peaks in adolescence.
Pathophysiology[edit]
T-ALL is characterized by the malignant transformation and proliferation of immature T cells, or T lymphoblasts. This is often associated with genetic abnormalities, such as translocations and mutations, that disrupt normal T cell development.
Clinical presentation[edit]
Patients with T-ALL typically present with signs and symptoms of bone marrow failure, such as fatigue, pallor, and bleeding, as well as lymphadenopathy, hepatosplenomegaly, and sometimes mediastinal mass.
Diagnosis[edit]
The diagnosis of T-ALL is based on the morphological, immunophenotypic, and genetic analysis of peripheral blood and bone marrow samples. The presence of T lymphoblasts in these samples is indicative of T-ALL.
Treatment[edit]
The treatment of T-ALL involves intensive chemotherapy, often followed by stem cell transplantation in high-risk cases. Despite advances in treatment, the prognosis of T-ALL remains poor, particularly in adults.
Prognosis[edit]
The prognosis of T-ALL is generally worse than that of B-cell ALL, with lower rates of complete remission and higher rates of relapse. However, recent advances in treatment have improved the prognosis of T-ALL, particularly in children.
See also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
